Duration of antiestrogenecity of compound CDRI-85/287: a new orally active nonsteroidal antiimplantation agent.
Indian J Exp Biol
;
1992 Nov; 30(11): 968-71
Article
in English
| IMSEAR
| ID: sea-56354
ABSTRACT
Duration of antiestrogenic and antiimplantation action of CDRI-85/287, (2-(4-(2-N-piperidino)ethoxy phenyl)-3-phenyl(2H)benzo(2)pyran), was studied in rat. Pretreatment of ovariectomized immature rats with this compound caused translocation of cytoplasmic estrogen receptor (ER) to the nucleus and a marked depletion of cytoplasmic ER pool resulting in a nonresponsive state of the uterus to subsequent estrogen administration until day 4. While in rats pretreated with estradiol, increased cytoplasmic ER level made the uterus responsive to a second injection of estrogen. In the delayed implantation model, 85/287 pretreated rats were given estrone on days 4, 5 or 6 post-antiestrogen treatment. No implantations were observed after estrone administration on day 4, but were present when estrone was given on days 5 or 6. Summation of these results suggests the duration of action of 85/287 to be 3-4 days in rat.
Full text:
Available
Index:
IMSEAR (South-East Asia)
Main subject:
Piperidines
/
Rats
/
Uterus
/
Benzopyrans
/
Female
/
Ovariectomy
/
Receptors, Estrogen
/
Cell Nucleus
/
Administration, Oral
/
Rats, Sprague-Dawley
Language:
English
Journal:
Indian J Exp Biol
Year:
1992
Type:
Article
Similar
MEDLINE
...
LILACS
LIS